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Abstract
It has been hypothesized that HLA class II alleles associated with rheumatoid arthritis (RA)
preferentially present self-antigens altered by post-translational modification, such as citrulli-
nation. To understand the role of citrullination we tested four RA-associated citrullinated epi-
topes and their corresponding wild-type version for binding to 28 common HLA class II.
Binding patterns were variable, and no consistent impact of citrullination was identified.
Indeed, in one case citrullination significantly increased binding compared to the WT pep-
tide, in another citrullination was associated with a reduction in promiscuity by 40%. For a
more comprehensive analysis, we tested over 200 citrullinated peptides derived from
vimentin and collagen II for their capacity to bind the RA-associated shared epitope alleles
DRB1*01:01 and DRB1*04:01. The overall effect of citrullination on binding was found to
be relatively minor, and only rarely associated with 3-fold increases or decreases in affinity.
Previous studies have suggested that citrullination of MHC anchor residues, in particular
P4, is associated with generation of novel RA-associated epitopes. However, analysis of the
predicted MHC-binding cores of all peptides tested found that in modified peptides with
increased binding affinity the citrullinated residue was predicted to occupy an anchor posi-
tion in only a minority of cases. Finally, we also show that identification of citrullinated pep-
tide binders could be facilitated by using the NetMHCIIpan 3.1 algorithm, representing
citrullination as a wildcard. Our studies identify a total of 117 citrullinated peptides that
bound RA-associated alleles with an affinity of 1000 nM or better.
Introduction
The HLA-DRB1 locus is associated with rheumatoid arthritis (RA) in most racial groups and
accounts for approximately one-third of the genetic susceptibility to RA [1, 2]. The Shared Epi-
tope (SE) is a conserved amino acid sequence at positions 70–74 in the third hypervariable
region of the DRB1 chain shared between RA-associated alleles (e.g., DRB104:01 and
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DRB101:01) and contributes to the P4 peptide-binding pocket. The presence of SE is the sin-
gle most significant genetic risk factor for RA [3]. It has been shown that 65–85% of RA
patients carry at least one MHC class II risk allele (i.e., SE+) [4–7], as opposed to protective
alleles (SE-), such as HLA-DRB104:02 [3, 8]. The SE not only confers a higher risk for RA,
but also increases the likelihood of developing a more severe form of the disease [9]. SE-coding
HLA-DRB1 alleles are associated with earlier onset of arthritis and more severe bone erosion
[10]. Furthermore, there is evidence of a gene-dose effect, in which the severity of bone
destruction in RA correlates positively with the number of SE-coding HLA-DRB1 alleles
[7, 11].
Over the past decade, a central role has been recognized for post-translational modifica-
tions, with particular emphasis on citrullination, in the pathogenesis of RA [12, 13]. Citrullina-
tion is a post-translational modification of arginine by peptidylarginine deiminase (PAD)
enzymes and is increased in response to stress/inflammation. This modification results in a
loss of net positive charge, and has been proposed to increase the peptide binding affinity of
citrullinated peptides to SE+ alleles [14]. In the context of autoimmune disease, citrullination
may thus promote generation of high-affinity citrullinated (and not arginine-containing) neo-
autoantigens, triggering activation of autoreactive T and B cells and inducing an autoimmune
response. By contrast, protective HLA molecules may be able to bind both arginine and citrul-
line, leading to negative selection of the recognizing T cells, thereby preserving tolerance to
these autoantigens. Supporting this hypothesis, it has been shown that (i) citrullinated fibrino-
gen could induce arthritis in DRB104:01 transgenic mice [15], (ii) proinflammatory cytokines
were produced by CD4+ T cells in SE+ individuals in response to citrullinated self-epitopes
[16], (ii) citrulline-specific Th1 and Th17 cells are increased in HLA-DRB104:01+ RA patients
[17, 18], and (iii) RA patients display Th17 cells responding to arthritogenic citrullinated
aggrecan [19]. Furthermore, Anti-Citrullinated Protein Antibodies (ACPA) recognizing vari-
ous citrullinated antigens such as fibrinogen, vimentin or collagen type II, are highly specific
for RA and are detected in approximately 70% of RA patient sera [20–23]. ACPA-positive indi-
viduals have the highest risk of RA [24–27]. Indeed, ACPA-positivity was found to be associ-
ated with a 10-fold increased risk overall, and a 33-fold increased risk of RA onset within 5
years [28]. Moreover, the presence of ACPA is also predictive of a more severe disease course
[29–31] and it has been further shown that passive transfer of ACPA in mice with existing
minimal joint disease exacerbates disease [32] and promotes bone destruction [33]. In addi-
tion, the individuals harboring both risk HLA-DR SE-positive alleles and any ACPA have the
highest risk for RA and more severe progression of the disease [31]. Importantly, ACPAs
emerge before onset of disease (up to 14 years prior to disease) and show a marked increase
about 2 years prior to RA diagnosis [28, 34]. This offers an opportunity for early interception
in a stratified patient subset (SE+, ACPA+ asymptomatic “patients”) and underlines the need
to better understand the impact of citrullination on autoimmune responses.
It has been hypothesized that RA-predisposing HLA-DR SE+ alleles bind arthritogenic pep-
tides whose affinity is increased by posttranslational modification (e.g., citrullination) [14].
Studies by Scally et al. [35] and others [14] proposed that while both predisposing and protec-
tive alleles bind citrullinated peptides, only the protective alleles bind the native peptide. It has
also been hypothesized that autoimmune epitopes are associated with unique binding proper-
ties and lower affinities or different patterns of specificity [36], and that citrullination might
impart unique binding properties to modified peptides, underlying the development of auto-
antigen specific T cell responses.
To experimentally address these points, we measured binding affinities of native and citrulli-
nated versions of several arthritogenic peptides using an in vitro assay and a panel of 28 widely
expressed HLA class II purified molecules, with a particular focus on SE- vs SE+ HLA-DR
Effect of citrullination on HLA class II binding
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alleles. We also tested a large panel citrulline modified (cit) peptides derived from vimentin and
collagen II, and their corresponding WT version, for their capacity to bind the SE+ alleles
DRB101:01 and DRB104:01. Together, these studies revealed that in general the effect of
citrullination on binding is minor, with the vast majority of cases resulting in little positive or
negative difference in binding affinity. Further, after determining the specific frames in which
each peptide bound the SE+ DRB101:01 and DRB104:01 alleles, we found that increases in
binding could more often be attributed to modification of non-anchor residues. Finally, we
demonstrate that the use of HLA class II binding algorithms representing citrullinated amino
acids as wildtype (“X”), when combined with in vitro binding assays, are an efficient means to
predict and identify potential citrullinated epitopes.
Methods
MHC purification and peptide binding studies
Purification of HLA class II MHC molecules by affinity chromatography, and the performance
of assays based on the inhibition of binding of a high affinity radiolabeled peptide to quantita-
tively measure peptide binding, were performed essentially as detailed elsewhere [37]. Briefly,
EBV transformed homozygous cell lines were used as sources of MHC molecules. A high affin-
ity radiolabeled peptide (0.1–1 nM) was co-incubated at room temperature or 37˚C with puri-
fied MHC in the presence of a cocktail of protease inhibitors. Following a two-day incubation,
MHC bound radioactivity was determined by capturing MHC/peptide complexes on mAb
(HLA-DR: L243; HLA-DQ: SPVL3; HLA-DP: B7/21) coated Lumitrac 600 plates (Greiner Bio-
one, Frickenhausen, Germany), and measuring bound cpm using the TopCount (Packard
Instrument Co., Meriden, CT) microscintillation counter. The concentration of peptide
yielding 50% inhibition of the binding of the radiolabeled peptide was calculated. Under the
conditions utilized, where [label]<[MHC] and IC50 [MHC], the measured IC50 values are
reasonable approximations of the true Kd values [38, 39]. Each competitor peptide was tested
at six different concentrations covering a 100,000-fold range, and in three or more indepen-
dent experiments. As a positive control, the unlabeled version of the radiolabeled probe was
also tested in each experiment. Peptides were purchased from Mimotopes (Victoria, Australia)
and/or A and A (San Diego) as crude material on a 1 mg scale, or purified (>95%) by reverse
phase HPLC. Binding predictions, and prediction of peptide binding cores, were performed
using the NetMHCIIpan-3.1 algorithm (www.cbs.dtu.dk) [40].
Selection of a panel of 28 common class HLA II molecules
For HLA-peptide binding studies, we selected a panel of HLA class II molecules (S1 Table)
representing common specificities in the general population [41], as well as a range of SE/non-
SE associated motifs [42]. The panel included several HLA-DRB1 “protective alleles” associ-
ated with non-SE motifs, and found to have Odds Ratio (OR) values less than 1 (see [42]).
These protective alleles included 3 HLA-DRB1 alleles (0402, 1302 and 1501) associated with
the S1 motif (ARAA or ERAA; OR = 0.39) and 3 (1101, 1201 and 1602) with the S3D motif
(DRRAA; OR = 0.37). We further included four “neutral” HLA-DRB1 alleles (0301, 0701,
0802 and 0901) that do not have a specific SE motif, and that are associated with OR = 1.00.
Finally, we selected 5 HLA “predisposing” alleles, to include four (0101, 0404, 0405 and
1001) with the S3P motif (Q/R RRAA; OR = 1.61), and one (0401) with the S2 motif (KRAA;
OR = 3.21). Four to five allelic variants each were also selected to represent the HLA-DRB3/4/
5, HLA-DQ and HLA-DP loci. These molecules are not particularly associated with RA or SE,
but are nevertheless expressed alongside HLA-DRB1 alleles. The phenotypic frequency at
which each molecule is expressed in the general population is also shown in S1 Table.
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Population coverage was calculated as previously described [41, 43]. Gene frequencies (gf) for
each HLA allele were calculated from population frequencies obtained from DbMHC (NCBI;
[44]). Phenotypic frequencies (pf) were calculated utilizing the binomial distribution formula:
pf = 1 − (1 − ∑gf)2, assuming no linkage disequilibrium.
Results
HLA binding affinity and specificity of RA-associated epitopes
To investigate the effects of citrullination on HLA class II binding, we first selected a panel of
T cell epitopes previously described as potentially arthritogenic when citrullinated (Table 1),
including fibrinogen 78–91 [15, 16], aggrecan 84–103 [16, 19, 45, 46], vimentin 66–78 [17, 18]
and collagen II 1236–1249 [16]. For each, we tested both the wild-type (WT) and citrullinated
(cit) versions for their capacity to bind a panel of 28 common HLA class II [41], including a
range of SE/non-SE associated variants [42] (see S1 Table). To benchmark affinity and speci-
ficity measures, we also tested the promiscuous influenza HA 307–319 T cell epitope [47, 48].
Confirming previous reports, HA 307–319 bound 15/19 HLA-DR alleles tested (but only 1/9
non-DR HLA class II) with an IC50 <1000 nM (Table 1), including all 5 SE+ alleles and 5/6 SE-
alleles. Also shown in Table 1, the citrullinated version of fibrinogen 78–91 bound only one of
the 28 alleles, and the unmodified WT version bound just two. Thus, citrullination has little
effect on binding of this non-promiscuous HLA class II binding epitope. Aggrecan 84–103 [16,
19, 49], on the other hand, was relatively promiscuous, binding a total of 15/28 HLA tested
including all 5 SE+, and 3/6 SE-, alleles. By contrast, the citrullinated version bound only 9
alleles and lost binding to 4 alleles, including 2 SE+ alleles (DRB101:01 and DRB110:01).
Thus, citrullination has an indiscriminate negative effect on this promiscuous binder.
Vimentin 66–78, in both WT and citrullinated forms, has been described as
DRB104:01-restricted [17]. The WT peptide bound only 5/28 HLA tested (Table 1), while the
citrullinated version bound of 12/28 alleles, including all 5 predisposing alleles and 3/6 protec-
tive alleles. Increases in binding with citrullination were in most cases over 20-fold, and in sev-
eral cases >100-fold. Thus, citrullination of the vimentin epitope increased binding capacity,
in particular for RA predisposing specificities. By contrast, both the WT and citrullinated ver-
sions of collagen II 1236–1249, which is associated with T cell responses of undefined restric-
tion [16] bound 11 of the 28 HLA tested, including 4/5 SE+ alleles and 1/6 SE- alleles, with
almost identical affinities.
Taken together, this data shows that RA-associated epitopes in their WT and citrullinated
forms have variable binding patterns to HLA class II alleles, and a consistent impact of citrulli-
nation is not apparent. That is, some citrullinated peptides bind better, some bind the same,
and others bind worse, than their cognate wild-type sequence.
Position of citrullination and influence on binding capacity of known
epitopes
Previous studies have suggested that citrullination has an impact when it occurs at an anchor
position, and in particular P4. This observation, along with the data above, suggests that citrul-
lination may generate novel epitopes in two ways. First, a new epitope may be generated
through substantially increased MHC class II binding capacity by modification at an MHC
contact residue (i.e., an anchor residue). Alternatively, a new epitope by be generated through
modification at a non-anchor residue that would be available for contact with a specific TCR.
To see if these patterns might be reflected in the above data, we utilized the NetMHCIIpan
3.1 tool (version 3.1, as hosted at www.cbs.dtu.dk) [40] to predict the peptide-binding core for
Effect of citrullination on HLA class II binding
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each of the four T cell epitopes tested above. For the present analysis, we focused on the 15
DRB1 alleles, for which a canonical P1-P4-P6-P9 anchor spacing has been generally described
[50, 51]. For each epitope and allele, we predicted the core for each WT epitope, and deter-
mined the relative position of citrullination.
As shown in Table 2, in only 11 of 60 cases (18.3%) did citrullination result in a 3-fold or
greater increase in binding capacity. In 35/60 (58.3%) cases the effect of citrullination on
Table 1. HLA class II binding of RA-associated epitopes1.
Group Allele HA 307–319 Fibrinogen 78–91 Aggrecan 84–103 Vimentin 66–78 Collagen II 1236–
1249
WT2 WT Cit WT Cit WT Cit WT Cit
SE+ DRB1*01:01 4.2 - 15655 155 3863 3256 9.5 81 232
DRB1*04:01 33 - 12878 713 827 13109 1.8 9.7 13
DRB1*04:04 751 2049 2323 565 854 206 9.0 102 216
DRB1*04:05 59 12770 11260 183 47 3957 54 1766 7343
DRB1*10:01 206 3578 8484 643 2416 5167 35 375 432
SE- DRB1*04:02 12 - - 501 4264 927 14 118 211
DRB1*11:01 126 13892 - 520 29652 11831 8924 9855 -
DRB1*12:01 1233 27769 9377 1048 11024 15874 2220 - -
DRB1*13:02 45 - - 268 552 11442 15033 3915 8288
DRB1*15:01 797 - - 1007 7600 4.1 5.4 1457 15165
DRB1*16:02 350 8432 15268 20460 22841 1080 118 23114 -
Other DR DRB1*03:01 4257 - - 530 11145 12207 25930 159 72
DRB1*07:01 385 - - 3034 8475 - 7306 29581 -
DRB1*08:02 1082 457 35746 3959 16957 53 275 1037 2148
DRB1*09:01 824 11063 - 730 28476 1415 353 315 276
DRB3*01:01 4309 - - 8464 18930 - - 68 63
DRB3*02:02 456 - - 245 51 9086 - 262 481
DRB4*01:01 462 7696 12685 955 2341 2023 4.0 80 7.3
DRB5*01:01 75 23 9.2 16 740 2228 1360 8880 10187
DP DPB1*02:01 24753 - - 14833 2768 - - - -
DPB1*04:01 39067 - - 26153 16155 - - - -
DPB1*04:02 1900 14564 23530 2143 13264 - - - -
DPB1*05:01 15236 16209 20823 7043 19539 9411 11946 - -
DQ DQB1*02:01 4786 - - 2542 783 - - 413 198
DQB1*03:01 19944 - - 229 382 2095 2009 12781 4118
DQB1*03:02 - - - 2444 4122 - - - -
DQB1*05:01 37206 - 37424 2641 7117 - - - 10320
DQB1*06:02 389 - - 630 513 11 25 1342 1525
Alleles bound SE+ 5 0 0 5 3 1 5 4 4
SE- 5 0 0 3 1 2 3 1 1
Other DR 5 2 1 5 2 1 3 5 5
DP 0 0 0 0 0 0 0 0 0
DQ 1 0 0 2 3 1 1 1 1
Total 16 2 1 15 9 5 12 11 11
1. Epitopes sequences, where X indicates the position of citrullinated arginine: HA 307–319, PKYVKQNTLKLAT; Fibrinogen 78–91, NQDFTNXINKLKNS;
Aggrecan 84–103, VVLLVATEGXVRVNSAYQDK; Vimentin 66–78, SAVRLXSSVPGVR; Collagen II 1236–1249, LQYMXADQAAGGLR.
2. Binding expressed as IC50 nM, and a binder (highlighted with bold font) is defined as IC50 <1000 nM. A dash (-) indicates IC50 >30,000 nM.
https://doi.org/10.1371/journal.pone.0177140.t001
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Table 2. Predicted HLA DR binding cores of four known citrullinated RA-associated epitopes.
Epitope Sequence Pos of cit Allele Effect of cit on binding1 Predicted WT core
Sequence Pos of cit
Fibrinogen 78–91 NQDFTNRINKLKNS 7 DRB1*01:01 Neutral FTNRINKLK 4
DRB1*04:01 Neutral FTNRINKLK 4
DRB1*04:04 Neutral FTNRINKLK 4
DRB1*04:05 Neutral FTNRINKLK 4
DRB1*10:01 Neutral FTNRINKLK 4
DRB1*04:02 Neutral DFTNRINKL 5
DRB1*11:01 Neutral FTNRINKLK 4
DRB1*12:01 Neutral FTNRINKLK 4
DRB1*13:02 Neutral DFTNRINKL 5
DRB1*15:01 Neutral FTNRINKLK 4
DRB1*16:02 Neutral FTNRINKLK 4
DRB1*03:01 Neutral DFTNRINKL 4
DRB1*07:01 Neutral FTNRINKLK 4
DRB1*08:02 Decreased FTNRINKLK 4
DRB1*09:01 Neutral FTNRINKLK 4
Aggrecan 84–103 VVLLVATEGRVRVNSAYQDK 10 DRB1*01:01 Decreased LVATEGRVR 7
DRB1*04:01 Neutral LVATEGRVR 6
DRB1*04:04 Neutral VLLVATEGR 9
DRB1*04:05 Increased VLLVATEGR 8
DRB1*10:01 Decreased LVATEGRVR 6
DRB1*04:02 Decreased VRVNSAYQD -1
DRB1*11:01 Decreased LVATEGRVR 6
DRB1*12:01 Decreased LLVATEGRV 7
DRB1*13:02 Neutral VRVNSAYQD -1
DRB1*15:01 Decreased LVATEGRVR 7
DRB1*16:02 Neutral LVATEGRVR 7
DRB1*03:01 Decreased VATEGRVRV 5
DRB1*07:01 Neutral LVATEGRVR 7
DRB1*08:02 Decreased LVATEGRVR 6
DRB1*09:01 Decreased LVATEGRVR 6
Vimentin 66–78 SAVRLRSSVPGVR 6 DRB1*01:01 Increased VRLRSSVPG 4
DRB1*04:01 Increased VRLRSSVPG 4
DRB1*04:04 Increased VRLRSSVPG 4
DRB1*04:05 Increased VRLRSSVPG 4
DRB1*10:01 Increased VRLRSSVPG 4
DRB1*04:02 Increased VRLRSSVPG 4
DRB1*11:01 Neutral VRLRSSVPG 4
DRB1*12:01 Increased VRLRSSVPG 4
DRB1*13:02 Neutral LRSSVPGVR 1
DRB1*15:01 Neutral VRLRSSVPG 4
DRB1*16:02 Increased VRLRSSVPG 4
DRB1*03:01 Neutral LRSSVPGVR 2
DRB1*07:01 Increased LRSSVPGVR 1
DRB1*08:02 Decreased VRLRSSVPG 4
DRB1*09:01 Increased LRSSVPGVR 1
(Continued)
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binding was considered neutral, and in the remaining 14 (23.3%) negative. Citrullination was
predicted to be in P4 in 24/60 cases (40%), and P4 citrullination accounts for 8 of the 11 cases
(72.7%) where binding was increased. However, examining the data on an epitope-by-epitope
basis revealed that the vimentin 66–78 epitope accounts for 10 of the 11 cases where improved
binding was associated with citrullination of the P4 residue. For fibrinogen, by contrast, where
for 14/15 alleles examined citrullination did not result in improved binding, the citrullination
was also predicted to be in P4. At the same time, for collagen II, where the binding of the WT
and citrullinated peptides were largely identical, in all cases the citrullination of the non-
anchor P2 and P3 residues was predicted. Finally, for aggrecan, where citrullination has a dele-
terious influence on binding for 8 DRB1 alleles, in 4 cases the citrullination was in the P6
anchor position, but deleterious influences were also noted for citrullination at the P5 and N-1
non-anchor positions, and the P7 secondary anchor [50].
The analyses in this section confirm previous observations that citrullination at the P4 posi-
tion may generate peptides with much improved HLA DRB1 MHC class II binding capacity,
but it is also evident that in other cases citrullination at P4 has no effect. Citrullination at other
positions, both anchor and non-anchor, has a largely neutral or, less often, deleterious effect
on binding capacity. These observations support the suggestion that generation of citrullinated
epitopes may be the result of either increased MHC class II binding or TCR recognition.
Effect of citrullination on binding affinity to two SE+ alleles is generally
minor
Next, we sought to extend the analysis to a larger set of unbiased peptides. Accordingly, we
generated a set of 15-mer peptides, overlapping by 10 residues, to span the entire protein
sequence of vimentin (acc. No. P08670). Each of the 76 peptides containing an endogenous
R residue was synthesized as well as analog peptides representing R to citrulline substitu-
tions. In cases where the native peptide contained multiple R residues, multiple analogs
Table 2. (Continued)
Epitope Sequence Pos of cit Allele Effect of cit on binding1 Predicted WT core
Sequence Pos of cit
Collagen II 1236–1249 LQYMRADQAAGGLR 5 DRB1*01:01 Neutral YMRADQAAG 2
DRB1*04:01 Neutral MRADQAAGG 2
DRB1*04:04 Neutral MRADQAAGG 2
DRB1*04:05 Decreased YMRADQAAG 3
DRB1*10:01 Neutral YMRADQAAG 2
DRB1*04:02 Neutral MRADQAAGG 2
DRB1*11:01 Decreased YMRADQAAG 3
DRB1*12:01 Neutral YMRADQAAG 2
DRB1*13:02 Neutral MRADQAAGG 2
DRB1*15:01 Decreased YMRADQAAG 2
DRB1*16:02 Neutral YMRADQAAG 3
DRB1*03:01 Neutral MRADQAAGG 2
DRB1*07:01 Neutral YMRADQAAG 3
DRB1*08:02 Neutral YMRADQAAG 3
DRB1*09:01 Neutral YMRADQAAG 3
1. When the binding capacity of both the WT and cit versions were >10,000 nM, effect on binding was considered neutral.
https://doi.org/10.1371/journal.pone.0177140.t002
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were made, each representing a single unique citrulline substitution; a total of 127 citrulli-
nated analogs were synthesized. The entire panel of 203 modified and unmodified peptides
was then tested for binding to purified HLA-DRB101:01 and HLA-DRB104:01. We
focused on these two alleles because both are SE+, and their binding specificities have been
well characterized in the literature. The binding data for each peptide tested is summarized
in S2 Table.
Fig 1 shows the HLA-DRB101:01 and HLA-DRB104:01 binding capacity of unmodified
wild type (WT) peptides versus the corresponding citrullinated analogs. In only 7 (5.5%) of the
127 cases for HLA-DRB101:01, and 8 (6.3%) for HLA-DRB104:01, did a citrullinated analog
bind with 3-fold or higher affinity than the corresponding WT peptide. Similarly, in only 13
(10.2%) cases for HLA-DRB101:01, and 3 (2.4%) for HLA-DRB104:01, did a citrullinated
analog bind with at least 3-fold lower affinity than the corresponding WT peptide. Considered
together, in 223 (87.8%) of the 254 cases considered binding capacity of the citrullinated pep-
tide was similar to that of the corresponding wildtype peptide.
Thus, as was the case with the known epitopes, in the majority of cases in an unbiased set of
peptides the effect of citrullination on HLA class II binding are minor (neutral). The analysis
also identified citrullinated vimentin peptides that bound with an affinity of at least 1000 nM
(a threshold previously associated with immunogenicity [50, 52, 53]) to either DRB101:01
(65 different epitopes), or DRB104:01 (22 epitopes). Of these, only 5 (7.7%) in the case of
DRB101:01, and 4 (18.2%) in the case of DRB104:01, bound with 3-fold or higher affinity
than the corresponding wildtype peptide.
Fig 1. Comparison of binding affinity of wild-type and citrullinated versions of vimentin peptides. Each data point indicates the DRB1*01:01 (left
panel) or DRB1*04:01 (right panel) binding capacity of WT vimentin peptides with the corresponding citrullinated version. Effects greater or less than
3-fold are demarcated by the diagonal dashed red lines and highlighted by red fill. Points to the lower right indicate instances where the citrullinated
peptide binds with higher affinity that the WT peptide, and vice versa.
https://doi.org/10.1371/journal.pone.0177140.g001
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Predicting citrullinated binders
Based on these results, showing relatively rare and minor differences between the citrullinated
and WT versions, we reasoned that existing predictive algorithms might be effectively
employed to predict citrullinated binders, and hence candidate epitopes. To test this hypothe-
sis, we predicted the HLA-DRB101:01 and HLA-DRB104:01 binding capacity of each WT
vimentin peptides tested above using the stand-alone version (v3.1) of the NetMHCIIpan algo-
rithm (as hosted at www.cbs.dtu.dk). For both alleles, the NetMHCIIpan algorithm was rea-
sonably efficient at predicting binding of the citrullinated peptide based on scores for the WT
peptide. For HLA-DRB101:01 a Spearman’s rank correlation (SCC) of 0.78, and an AUC
(area-under-the-curve) value of 0.90, was calculated using the binding classification threshold
of 1000 nM, and for HLA-DRB104:01 the SCC and AUC performance metrics were 0.67 and
0.83, respectively (data not shown).
To see if improved predictions could be obtained, we next employed a feature of the
NetMHCIIpan algorithm (version 3.1) that allows making predictions for peptides containing
wildcard amino acids (represented as an “X”). Using this property, we evaluated the predictive
performance by comparing the resulting predicted binding of the citrullinated peptides with
measured binding values (Fig 2). Doing this, we found improved and relatively high perfor-
mance values, with SCC = 0.84/0.70 and AUC = 0.91/0.82 for DRB101:01 and DRB104:01,
respectively.
Combination of HLA binding predictions for wild-type peptides and HLA
binding assays of citrullinated analogs identifies novel citrullinated
binders from collagen
To further evaluate the effectiveness of utilizing the NetMHCIIpan-3.1-based approach allow-
ing representation of citrullinated amino acids as wildcards to predict citrullinated analogs
that bind with high affinity, we examined an independent set of peptides. Accordingly, we
scored all R containing 15-mer peptides in collagen using NetMHCIIpan-3.1, single substitut-
ing native R residues with X. All citrullinated peptides predicted to bind HLA-DRB101:01
and/or HLA-DRB104:01 at the 1000 nM threshold [50, 52, 53]) were selected for synthesis; in
each case the corresponding WT peptide was also selected. As a result, 36 citrullinated peptides
and 29 corresponding WT versions were selected for HLA-DRB101:01, and 13 citrullinated
and 10 corresponding WT peptides were selected for HLA-DRB104:01. (All peptides pre-
dicted to bind DRB104:01 were also predicted to bind DRB101:01, a result that comports
with previous observations regarding the broad repertoire of DRB101:01 [41, 54, 55]). We
also selected a control set of 43 citrullinated peptides (and the corresponding 32 WT peptides)
predicted to be HLA-DRB101:01 and HLA-DRB104:01 non-binders (i.e., predicted affinity
>1000 nM).
These 140 collagen peptides (79 citrullinated, 61 WT) were tested for their capacity to bind
HLA-DRB101:01 and HLA-DRB104:01 (S2 Table). In the case of HLA-DRB101:01, 35 of
the 36 (97.2%) predicted citrullinated binders had an affinity of 1000 nM, or stronger. Seven
of 36 citrullinated peptides also bound with an affinity at least 3-fold stronger than the corre-
sponding WT peptide. By contrast, only 9/43 (20.9%) of the predicted non-binders bound
DRB101:01 at the same level (8/9 had predicted affinities in the 1000–5000 nM range). For
HLA-DRB104:01, 9 of the 13 (69.2%) of the predicted citrullinated binders had an affinity of
1000 nM or better, and 3 also bound with at least 3-fold stronger affinity than the correspond-
ing WT peptide. For the control peptides, 4/43 (9.4%) bound DRB104:01 at the 1000 nM level
(all 4 had predicted affinities in the 1000–2000 nM range).
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Finally, we again utilized the NetMHCIIpan tool (version 3.1) [40] to predict the MHC
binding cores of all of the citrullinated vimentin and collagen peptides tested, and the location
of the corresponding citrullination was determined (see S2 Table). As above, anchor positions
were defined as P1, P4, P6, P7 and P9. In 17 of the 206 (8.3%) cases for DRB101:01, and 13/
206 (6.3%) for DRB104:01 (S3 Table), citrullination resulted in an increase in binding. In just
4 of the 17 (23.5%) cases improved binding for DRB101:01, and 4/13 (30.8%) for DRB10401,
citrullination was predicted to be an anchor position. We also considered the possibility that
with citrullination the binding core shifts frame, and as a result situates the citrullinated resi-
due in a more optimal position (e.g., P4); this possibility is suggested as with the WT core-
based predictions none, or few, peptides are predicted to have the cit in the P1, P4 or P6
anchor positions. Accordingly, we also predicted the cores for each peptide/allele utilizing
NetMHCIIpan substituting native R residues with X. When this was done, only a slight change
in attribution was observed, with 6/17 increases for DRB101:01, and 6/13 for DRB104:01,
associated with citrullination of an anchor residue; in the majority of cases, increase in binding
were predicted to be with citrullination of a non-anchor residue. Fig 3 summarizes increases
in binding affinity as a function of the position of citrullination in the predicted peptide core
for binding DRB101:01 and DRB104:01, as evaluated by both approaches.
Together these results confirm in large set of peptides that the effect of citrullination on
peptide binding to two SE+ alleles associated with RA is, in general, minimal. They also reveal
that in the majority of instances of increased binding citrullination is predicted at a non-
anchor residue. Further, the analysis, which resulted in the identification of 45 citrullinated
peptides derived from collagen (highlighted with bold font in S2 Table) that bind HLA-
DRB101:01 and/or HLA-DRB104:01 with an affinity better than the 1000 nM threshold, and
Fig 2. Prediction of the DRB1*01:01 and DRB1*04:01 binding capacity of citrullinated peptides. The DRB1*01:01 (left panel) and DRB1*04:01
(right panel) binding capacity of citrullinated peptides were predicted using NetMHCIIpan version 3.1 predictions by substituting the citrullinated residues
with the wildcard “X”. Trend lines are show in red.
https://doi.org/10.1371/journal.pone.0177140.g002
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thus represent potential targets for additional study, confirms that binding affinity predictions,
at least for two SE+ DRB1 alleles, can accurately be approximated using NetMHCIIpan-3.1
using a wildcard representation of citrullinated amino acids.
Discussion
We report the first comprehensive survey of the effect of citrullination on HLA class II bind-
ing, with particular emphasis on two SE-associated alleles. Using four different RA-associated
epitopes and a panel of common HLA class II MHC we found that the effects of citrullination
on HLA binding are not generalizable, but rather peptide-dependent. In side-by-side experi-
ments with purified HLA, we demonstrate that in some cases citrullinated peptides bind well,
but in others they do not. Similarly, compared to the wild-type peptide, in some cases citrulli-
nation is detrimental, in others beneficial, and yet in others has no effect.
Binding of citrullinated peptides to HLA-DRB101:01 and HLA-DRB104:01 was further
examined using panels of peptides derived from vimentin and collagen. HLA-DRB101:01 and
HLA-DRB104:01 were chosen because they are represented with high frequency in the gen-
eral population, are associated with RA, and considered as prototypical SE+ alleles. Further-
more, most in vivo studies are performed using HLA-DRB101:01 and HLA-DRB104:01
transgenic mice, further highlighting the interest of in-depth study of these two alleles. With
these peptide panels, representing over 200 citrullinated peptide data points for each allele, no
consistent pattern could be associated with citrullination. As with the small set of known epi-
topes, in some cases, compared to the wild-type peptide, citrullination is detrimental, and in
others beneficial, but in the vast majority of cases citrullination has little effect on binding
capacity.
Fig 3. Increases in binding capacity due to citrullination is associated with modification at both anchor and non-anchor positions. The number
of instances of increased DRB1*01:01 (left panel) or DRB1*04:01 (right panel) binding associated with citrullination of arginine at specific peptide
positions relative to predicted core region frames is shown. Anchor positions are highlighted with red bars and non-anchor by blue bars. Light filled bars
show the total number of increases attributed to anchor (white filled red bars) and non-anchor (blue hatched bars) positions. Tabulations are shown for two
different approaches to defining the core residues, as described in the text.
https://doi.org/10.1371/journal.pone.0177140.g003
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Our data support the notion that citrullinated residues at P4 may be beneficial for binding
to HLA-DRB104:01. Indeed, taken together, increases in DRB104:01 and DRB101:01 bind-
ing with citrullination were more likely to be associated with P4 than other anchor positions.
However, it is also apparent that citrullination of P4 did not always lead to increased binding
capacity. In some cases the absence of increased binding may be the result of the presence of
sub-optimal residues at other main anchors, or deleterious residues at secondary positions,
leading to overall low affinity. Thus, it is possible to speculate that fibrinogen 78–91 is a
poor SE+ binder, despite the presence of F at the canonical P1 main anchor, because of the
presence of residues in other positions (e.g., D at N-1, or N at P3 and P6) that have deleterious
effects on binding capacity, thereby mitigating any potential benefit from citrullination. Mean-
while, citrullination of P4 of the vimentin epitope can result in increased DRB101:01 and
DRB104:01 binding because residues in the canonical anchor positions (i.e. V in P1, S in P6
and V in P9) are very well tolerated.
But, our results also challenge the classical view that citrullinated residues are only accom-
modated within the P4 pockets of HLA-DRB101:01 and HLA-DRB104:01 by showing that
citrullination may be “tolerated” or even beneficial at different positions. In agreement with
this data, James et al [56] have described that HLA-DRB110:01 presents RA-associated citrul-
linated peptides by accepting citrulline in three of its binding pockets. Similarly, a recent study
by Kampstra et al. showed for several HLA-DQ molecules enhanced affinities for citrulline
compared to arginine residues in multiple peptide-binding pockets, including pockets 4, 6, 7,
and 9 of HLA-DQ2 and pockets 1, 6, and 9 of HLA-DQ7 and HLA-DQ8 [57]. Further, Roark
and co-workers [58], studying the binding of RA associated epitopes, including collagen II
258–272 and vimentin 66–78, for their capacity to bind DRB101 subtypes with differential
associations with RA susceptibility, identified a role for the MHC B chain residue in position
86, associated with the P1 anchor, in disease susceptibility.
A recent study by Gerstner et al. [59] examined the capacity of native and citrullinated ver-
sions of alpha-enolase derived epitopes to bind DRB104:01, DRB104:04 and DRB101:01.
Interestingly, in six of the eight cases both versions of the same epitope bound all 3 alleles with
similar affinity (i.e., within 3-fold); for one epitope, the citrullinated peptide bound substan-
tially better to two alleles, and for another epitope the citrullinated peptide bound one allele
with higher affinity. This overall rate of improved binding (3/24, 12.5%) is not entirely dissimi-
lar from that observed in our analysis. Also in agreement with our results, Gerstner and co-
workers found that the citrullinated residues are in various positions, including the canonical
P4, P6 and P7 anchors, but also non-anchor positions, to include P-2, P2, P10 and P11; how-
ever, in two of the three cases of improved binding citrullination was in P4. Using crystal struc-
tures, the same study was able to determine, in the case of one DRB104:01 epitope, that T cell
specificity was for the citrullinated residue.
Our data also show that citrullination of different positions within the canonical 9-mer
MHC binding core does not have a consistent effect on binding capacity. While citrullination at
an HLA anchor residue could increase binding capacity in some cases, in the majority of cases
of increased binding citrullination was associated with a non-anchor residue. But also, our data
show that in the vast majority of cases citrullination, whether at an anchor or non-anchor posi-
tion, has little effect of binding capacity. Thus, the present results suggest that while novel RA-
associated epitopes may result from generation of epitopes with increased binding, it is also
likely that a large number of citrullinated epitopes are the result of novel TCR interactions.
Together, these data reinforce the need and use of a refined methodology for identifying citrul-
linated peptide binding beyond the P4 pocket. Using mass spec analyses of peptides eluted from
the RA-associated DRB101:01, DRB104:01 and DRB110:01 alleles, as well as non-RA associ-
ated alleles, Scholz et al. [60] found some sequence patterns common to peptides bound to the
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RA-associated alleles, but not present in the non-RA-associated repertoire. However, overall,
the degree of repertoire overlap between the alleles studied was found to be a low.
Accordingly, we demonstrated that combination of existing predictive algorithms and in vitro
testing can identify citrullinated peptides that bind HLA-DRB101:01 and HLA-DRB104:01
with high affinity, and therefore represent potential epitopes. The performance of this approach
was validated using human collagen and vimentin as test cases, and demonstrated that binding
of citrullinated peptides could be very accurately predicted using NetMHCIIpan version 3.1 rep-
resenting citrullinated amino acids as wildcard (“X”).
In this context, our study has identified 117 citrullinated peptides that bind HLA-DRB101:01
and/or HLA-DRB104:01 with an affinity<1000 nM, a threshold previously identified with the
vast majority of HLA class II restricted epitopes [50, 52, 53]. Whether with improved binding or
not, compared to the wild-type peptide, these epitopes could be perceived as a new non-self
entity by the immune system and thus trigger autoimmune reactions. This study thus represents
a large increase in knowledge regarding potential citrullinated epitopes associated with RA.
When we examined the citrullinated 1000 nM binders identified herein we found that only 10
overlapped (or were nested with) vimentin and collagen citrullinated epitopes previously
described in the literature, as judged by a query of the IEDB on October 2016 [61].
The present study also has potential implications in terms of our understanding of the
impact of citrullination on recognition of epitopes in the context of SE alleles. Most studies
have focused on modulation of HLA binding, while our study shows that in most cases the
effect on binding is rather minor. This suggests that citrullination may be more likely to
influence T cell recognition rather than HLA binding. Indeed, it has also been shown that
citrullination, depending upon the position it is located, could create a new HLA-DR-
restricted functional T cell epitope. In this respect, Chemin et al. have shown that the
HLA-DRB110:01-restricted citrullinated-CII 311–325 epitope is a neo T cell epitope where
citrulline is in position P2, where it would affect T cell recognition [62]; Gerstner et al. [59]
have also made similar observations in the context of an alpha-enolase T cell epitope restricted
by DRB104:01. Thus, the second potential effect of converting arginine to citrulline in a pep-
tide is that it generates a novel TCR interaction site on the peptide when it is bound and pre-
sented by the SE+ HLA-DR molecule.
Additional studies will aim at correlating the epitope prediction with the T cell reactivity
towards these predicted epitopes in HLA-DRB101:01 and/or HLA-DRB104:01 RA patients.
The determination of the frequencies of predicted citrullinated peptide-specific CD4+ T cells
in RA patients (ideally with different disease severity scores versus healthy controls) using
MHC II tetramers along with the characterization of the phenotypic (i.e., memory, naïve, Treg
CD4+ T cells) and functional (i.e., cytokine profile produced upon antigen stimulation) nature
of the responding T cell repertoire will help to further highlight the relevance of this methodol-
ogy in regard to RA pathogenesis [16–18, 35].
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